COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank

BMC Neurology

Table 3 Risk of COVID-19 among individuals with neurodegenerative diseases, by time since the first diagnosis, compared to individuals without such conditions

	No.(%)of Any COVID-19		Odds Ratio	No.(%)of Inpatient COVID-19		Odds Ratio	No.(%)of COVID-19 related death		Odds Ratio
	Exposed	Unexposed	(95% CI)	Exposed	Unexposed	(95% CI)	Exposed	Unexposed	(95% CI)
Time since the first diagnosis of neurodegenerative diseases, years
< 1	82/309 (26.5)	17,220/93658 (18.4)	2.56 (1.97–3.32)	49/309 (15.9)	5370/93658 (5.7)	2.45 (1.79–3.36)	19/309 (6.1)	986/93658 (1.1)	2.81 (1.73–4.57)
1–2	289/1009 (28.6)		2.70 (2.34–3.12)	158/1009 (15.7)		2.37 (1.98–2.83)	84/1009 (8.3)		3.92 (3.08–5.01)
3–4	145/549 (26.4)		2.42 (1.99–2.95)	72/549 (13.1)		1.95 (1.51–2.51)	49/549 (8.9)		4.45 (3.25–6.09)
≥ 5	202/750 (26.9)		2.27 (1.92–2.68)	100/750 (13.3)		1.99 (1.60–2.47)	43/750 (5.7)		2.89 (2.08–4.00)

Any COVID-19 includes a positive test result from PHE, or an inpatient diagnosis from UK Biobank inpatient hospital data or a death cause of COVID-19 infection
Odds Ratio (95%) were derived from logistic regression models, which were adjusted for birth year, sex, race/ethnicity, body mass index, smoking, alcohol use, Townsend deprivation index, annual household income, educational attainment, and Charlson Comorbidity Index (dementia excluded)

ISSN: 1471-2377